“A loved one has HR + Her2 + multifocal right breast cancer with residual disease after hormone therapy. They put her on cvc type picc and she is given chemotherapy for the first line of the advanced phase with the combination of Docetaxel + Trastuzumab + Pertuzumab. Can you explain to me if this chemotherapy has to be done by force and if there is any alternative?“
He answers Annamaria Molinoprofessor at the School of Medicine and Surgery of the University of Verona, former Director of the Complex Operating Unit of Medical Oncology and of the Breast Group at the Integrated University Hospital of Verona.
Breast Health, the newsletter is born
Dear Reader,
it is impossible to give you an answer regarding the specific case of the person dear to you, as there is too much data relating to the patient, the disease and the treatments already performed, and in any case it would not be correct to speak without a clinical visit.
We can, however, make a couple of observations: the PICC is just a device that allows you to always have venous access available, saving the patient from annoying searches for a usable vein and ensuring that there will be no extravasation or phlebitis.
As for the therapeutic scheme you refer to, it is a highly effective treatment. It is true, as you suggest, that there are many therapeutic options in breast cancer, but if this scheme has been recommended, it is certainly the most suitable in the case in question. There are International and National Guidelines and stringent indications on the use of oncological drugs, and all oncologies follow the international and ministerial indications
Therefore, trust the oncologists who follow you with confidence.